These results suggest that CXCL12/CXCR4 is a potential therapeutic target for treating autoimmune diseases, including human immunodeficiency virus infection, cancer, warts, and immunodeficiency (Comba et al., 2020). This evidence concerns the gene CXCL12 and Immunodeficiency.